docetaxel anhydrous has been researched along with 4-imino-1,3-diazabicyclo(3.1.0)hexan-2-one in 1 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (4-imino-1,3-diazabicyclo(3.1.0)hexan-2-one) | Trials (4-imino-1,3-diazabicyclo(3.1.0)hexan-2-one) | Recent Studies (post-2010) (4-imino-1,3-diazabicyclo(3.1.0)hexan-2-one) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 47 | 8 | 7 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boytim, M; Dhillon, N; Dorr, R; Hersh, E; Hong, D; Kurzrock, R; La Paglia, A; Moulder, S; Naing, A; Ng, C; Tse, S; Wheler, J | 1 |
1 trial(s) available for docetaxel anhydrous and 4-imino-1,3-diazabicyclo(3.1.0)hexan-2-one
| Article | Year |
|---|---|
A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Demography; Docetaxel; Female; Hexanones; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prostatic Neoplasms; Reactive Oxygen Species; Taxoids; Treatment Outcome | 2010 |